GlassScriptPhysician profile
Alrich L Gray
NPI 1952372294
$33,840.82
in general payments reported to CMS, 2019-2025
27 companies · $4,703 in 2025
The $4,703 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,985 · 2020: $2,677 · 2021: $2,783 · 2022: $8,513 · 2023: $2,951 · 2024: $7,230 · 2025: $4,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,686 · Food and Beverage: $6,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,686.22 |
| Food and Beverage | $6,197.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $8,626.33 | 2021-2025 | Micra, Pulseselect, Na |
| Medical Device Business Services, INC. | $5,757.02 | 2022-2024 | Carto 3 |
| Abbott Laboratories | $4,780.15 | 2019-2025 | Optis, Diamondback Coronary, Mitraclip |
| Boston Scientific Corporation | $3,963.81 | 2019-2025 | Watchman Flx, Farapulse, Watchman Access System |
| Medtronic Vascular, INC. | $3,852.80 | 2019-2020 | |
| Atricure, INC. | $1,867.76 | 2021 | |
| Biosense Webster, INC. | $1,447.19 | 2019-2025 | Carto 3, Na |
| E.R. Squibb & Sons, L.L.C. | $504.67 | 2019-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $468.43 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $435.41 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $398.73 | 2019-2024 | Xarelto |
| Amgen INC. | $319.11 | 2019-2025 | Repatha |
| Pfizer INC. | $310.08 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $251.68 | 2021-2025 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $160.91 | 2023 | Arcalyst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $145.64 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.48 | 2019-2023 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $87.15 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $84.62 | 2023 | Optimizer |
| Abiomed | $72.61 | 2025 | |
| Preventice Services, LLC | $51.29 | 2019-2020 | |
| Cardiovascular Systems INC. | $42.82 | 2021 | |
| Sanofi-Aventis U.S. LLC | $27.62 | 2019 | |
| Chiesi USA, INC. | $25.18 | 2019 | |
| Philips North America LLC | $18.24 | 2019 | |
| Terumo Medical Corporation | $18.19 | 2025 | Heartrail |
| Cordis US Corp. | $13.90 | 2025 | Mynx Control Venous |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alrich Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.